What to Expect When You Join a Cardiovascular Clinical Trial

What is a clinical trial, in plain terms?

A clinical trial is a research study that tests a new medicine, medical device, or treatment approach in real patients to find out two things: does it work better than what we currently have, and is it safe enough to use widely? Cardiovascular clinical trials test new treatments for conditions like high blood pressure, heart failure, heart attacks, irregular heartbeats, peripheral artery disease, and structural heart problems.

Every approved medicine you've ever taken — from blood pressure pills to statins to clot-busters — was approved because clinical trial patients agreed to participate in studies that tested them. Without trial volunteers, we wouldn't have the treatments we have today.

Clinical trials happen in phases:

• Phase 1: First time the treatment is tested in humans. Small number of participants. Focus on safety and dose-finding.
• Phase 2: Larger group. Tests whether the treatment seems to work and continues to monitor safety.
• Phase 3: Large studies (often hundreds or thousands of patients across many sites). Tests whether the treatment works better than current standard care.
• Phase 4: After approval. Continues to monitor long-term safety in everyday use.

Most cardiovascular trials at sites like Amavita Research are Phase 2 or Phase 3 — meaning the treatment has already been tested for basic safety and we're now testing how well it works.

How does enrollment actually work? Step by step.

Step 1: Initial screening (15-30 minutes)

You — or your cardiologist — contact the trial site. If you contact us, we'll ask a few questions over the phone to check whether you might be eligible for any of our current trials. This is free and doesn't commit you to anything.

If there's a possible fit, we schedule a screening visit.

Step 2: Screening visit (1-3 hours)

At the screening visit, you meet the trial team. The Principal Investigator — a practicing cardiologist — reviews your medical history with you. We do basic measurements like blood pressure, an ECG, and a blood draw.

Before any of this, you go through informed consent. This is the most important part of the screening visit. You receive a detailed document — often 20 to 40 pages — that explains:

• What the trial is studying
• What participating involves
• What the known risks are
• What the potential benefits might be (and what they might not be)
• Your right to leave the study at any time
• How your private medical information will be protected

The team walks you through the document. You can ask any question, as many times as you want. You can take the document home and discuss it with family or your regular doctor before deciding. You sign nothing until you're ready.

Important: signing the consent form is not a commitment. You can withdraw at any point during the trial without giving a reason and without it affecting your future medical care. For a section-by-section walkthrough of what's in the form and what to look for, see our consent-form reading guide.

Step 3: Eligibility confirmation (a few days to a couple of weeks)

After the screening visit, the trial team reviews your medical history and screening results against the trial's eligibility criteria. Not everyone who screens is eligible — trials are usually designed for specific patient profiles. If you're not eligible for one trial, you may be eligible for another.

If you're eligible, we contact you to schedule the first study visit.

Step 4: Randomization (for most Phase 2 and Phase 3 trials)

In many trials, patients are randomly assigned (like a coin flip) to either receive the new treatment or to receive standard care. Neither you nor the trial team chooses which group you're in. This is how researchers prove the new treatment actually works rather than just hoping it does.

In some trials, this is "double-blind" — meaning neither you nor the trial team knows which group you're in until the study ends. Other trials are "open-label" where everyone knows.

This part bothers some patients. It's worth understanding the reason: if patients or doctors could choose, the results would be biased and we'd never know whether new treatments actually work. Randomization is the only fair way to find out.

Step 5: The study itself

Depending on the trial, the study can last from a few weeks to several years. Most cardiovascular trials we run involve:

• Regular study visits (every 1-3 months typically)
• Blood work and ECGs at most visits
• Sometimes echocardiograms, ambulatory blood pressure monitoring, or other tests
• Taking the study treatment (a pill, an injection, an infusion, or a procedure) according to the protocol
• A diary or app where you record symptoms, medication adherence, or other data
• Phone check-ins between visits

Most cardiovascular trial visits take 1-3 hours. The trial site coordinates around your schedule when possible.

Step 6: End of study and follow-up

When the trial ends — for you individually or for the whole study — there's typically a final visit where you return any unused study treatment and complete final assessments. Many trials include a follow-up period (3, 6, or 12 months) where the site stays in touch to monitor long-term outcomes.

After the study ends, you return to your regular cardiologist for ongoing care. If the new treatment was approved or has continued availability, your doctor may be able to prescribe it for you.

How safe is participation?

This is the question every patient asks. The honest answer is: clinical trials are not risk-free, but they are highly regulated.

What protects you:

• Every trial at every legitimate site is reviewed and approved by an Institutional Review Board (IRB) — an independent committee of physicians, scientists, and community members whose job is to make sure the trial is ethical and the risks are reasonable.
• The trial team monitors you closely — usually more closely than routine care.
• Adverse events (any new symptom or problem that happens during the trial) are reported, tracked, and reviewed.
• Independent Data Safety Monitoring Boards review trial data periodically and can stop a trial early if they see safety problems.

What the risks actually are:

• Side effects from the study treatment. These are listed in the consent form. Some are common, some rare, some serious.
• The treatment may not work for you. Randomization may put you in a group that doesn't get the new treatment.
• Time commitment. Trial visits take time and energy.
• Inconvenience — labs, ECGs, study-specific tests.

The trial team's job is to make sure you understand all of these before you sign. Take your time. Ask everything.

What about cost and compensation?

For most cardiovascular trials at Amavita Research:

• Study-related care is free to you. The trial sponsor pays for the study treatment, study visits, study labs, and study procedures.
• You may be reimbursed for travel, parking, or time at the rate the trial allows. Some trials offer per-visit stipends in the $50-$200 range. This varies by trial and is described in the consent form.
• Your regular medical care is still billed to your insurance as usual. The trial doesn't replace your regular cardiologist or your other doctors.

You should not be paying out-of-pocket for the study treatment itself. If a trial asks you to pay for the experimental treatment, that's a red flag and you should ask questions.

Your rights as a trial participant

You have specific rights that are protected by federal regulations:

1. The right to receive complete information about the trial, including risks, benefits, alternatives, and what will be expected of you.
2. The right to ask questions at any point and receive clear answers.
3. The right to withdraw at any time, for any reason, without it affecting your future medical care.
4. The right to confidentiality of your medical information per HIPAA.
5. The right to be informed of new findings during the trial that might affect your decision to continue.
6. The right to access the trial site's contact information so you can reach the team if you have questions or concerns between visits.

You also have the right to talk to a patient advocate or to contact the IRB directly if you have concerns the trial team isn't addressing.

Common questions

"What if I have a bad reaction?" The trial team manages it. You contact us, we see you, we treat the reaction. If it's serious, we may pause your participation in the trial. Either way, your medical care continues.

"Can I take my regular medications?" Usually yes, but the trial team needs to know all of your medications and supplements before you start. Some trials have specific prohibitions. The consent form lists these.

"What if I move or my schedule changes?" Tell the trial team. We can sometimes coordinate study visits with sites in other cities if you relocate. Schedule flexibility is something we plan around.

"Will my regular doctor know I'm in a trial?" With your permission, we communicate with your regular cardiologist and primary care doctor so your overall care is coordinated. You stay in control of who gets what information.

"Is this experimental? Am I a guinea pig?" The treatment is investigational — meaning it's being tested. It's not "experimental" in the sense of throwing things at the wall. The trial design is based on previous studies that have established basic safety. You're a research participant, which is a meaningful contribution — not a guinea pig.

How to decide whether to participate

The decision is yours. Some questions to ask yourself:

• Do I understand what the trial involves?
• Does my regular cardiologist agree it might be a good fit?
• Can I commit to the visit schedule?
• Am I doing this for the right reasons (potential benefit to myself, contribution to medical knowledge) and not the wrong reasons (financial pressure, fear of disappointing my doctor)?
• Have I had time to think about it without feeling rushed?

If the answer to any of these is "no" or "I'm not sure," it's OK to wait. It's OK to say no. Trials need volunteers who are informed and committed — not patients who feel pressured.

How to start

If you'd like to find out whether you might be eligible for a cardiovascular trial at Amavita Research:

• Call (786) 703-5941 for an initial 15-minute eligibility screening
• Or fill out the patient contact form at /contact-patient
• Or have your cardiologist refer you (we coordinate with most Miami-area cardiology practices)

You can also review our active trials and see which indications we're currently enrolling for.

We're located at 100 NW 170 Street, Suite 305, North Miami Beach, FL 33169. We see patients in English, Spanish, Haitian Creole, and Brazilian Portuguese.

---

About Amavita Research: Amavita Research is a cardiovascular clinical trial site embedded inside amavita Heart and Vascular Health®, a private cardiology practice in North Miami Beach, FL. Our Principal Investigators are practicing cardiologists who see patients every business day. We're IAOCR GCSA-certified, ICH-GCP E6(R3) compliant, and SCRS members.